多发性骨髓瘤的免疫治疗 - 中国病毒学论坛|我们一直在坚持！

Multiplemyeloma is the second most common hematologic malignancy. The treatment of thisdisease has changed considerably over the last two decades with theintroduction to the clinical practice of novel agents such as proteasomeinhibitors and immunomodulatory drugs. Basic research efforts towards betterunderstanding of normal and missing immune surveillence in myeloma have led todevelopment of new strategies and therapies that require the engagement of theimmune system. Many of these treatments are under clinical development and havealready started providing encouraging results. We, for the second time in thelast two decades, are about to witness another shift of the paradigm in themanagement of this ailment. This review will summarize the major approaches inmyeloma immunotherapies.

多发性骨髓瘤是第二种最常见的恶性血液系统疾病。在过去的二十年内，由于在临床上引进了新的治疗方案如蛋白酶抑制剂和免疫调节药物新型制剂，对于该疾病的治疗有了很大的改变。对于正常和缺失的免疫监控在多发性骨髓瘤中作用的基础研究的更好的理解，使得人们需要针对增强免疫系统的新的治疗策略的开发。这些治疗方法都是在临床试验中得到的发展，并已经开始取得令人鼓舞的结果。在过去的二十年中，我们将会见证第二次治疗技术的转变。本文将会总结以CAR-T为代表的多发性骨髓瘤的主要治疗方案。